Table of Contents(Germany)
1.1 Project Objectives5
1.2 Definitions7
1.3 German HealthCareSystem and Reimbursement9
1.4 German Laboratory Landscape14
1.5 RespondentPopulation Germany15
2.1 Sexual TransmittedDiseases(STD)17
- ChlamydiaTrachomatis19
- Neisseria21
- HIV22
- HCV23
- Group B Streptococcus24
- HSV25
2.2 Mycobacteria25
- MycobacteriaTuberculosis28
- MycobacteriaAvium29
- Mycobacteria?NA Purification31
2.3 AtypicalPneumoniae32
- Bordetella33
- Legionella33
- Chlamydiasp.34
- MycoplasmaPneumoniae35
2.4 Cytomegalovirus(CMV)36
- CMV ?Qualitative Tests37
- CMV ?Quantitative Tests37
2.5. ViralMeningitis38HSV 1 & 239
- Enterovirus41
- West NileVirus (WNV)41
- Epstein BarrVirus (EBV)42
- VZV43
2.6 RespiratoryViruses44
- SARS45
- Adenovirus46
- Influenza A46
- Influenza A&B47
- RSV48
- Parainfluenza48
2.7 HPV49
2.8 ChronicMeningitis50
2.9 BacterialMeningitis53
- NeisseriaMeningitis54
- HaemophilusInfluenza54
- Pneumococcae55
- Listeria55
- Enterobacteria56
2.10 Tick Born Encephalitis56
2.11 AntibioticResistantBacteria59
2.12 Candida61
3. Equipment & Purchase63
3.1 CurrentInstallations& Financingof Laboratory Equipment63
- Cobas Amplicor, Roche64
- Light Cycler, Roche64
- ABI PRISM, AppliedBiosystems64
- RotorGene, CorbettResearch64
- OtherCycler65
- OtherDevices/Manufacturers66
3.2 Budget Resources67
3.3 WhoisInvolvedin PurchasingDecisions70
3.4 Howdo LaboratoriesPurchase72
3.5 CriteriaInfluencea PurchasingDecision74
3.6 WhatareLaboratoriesWillingto PayforNew Tests? 75
4. Market Sizesand Market Shares 76
4.1 Market VolumesforSelectedPathogens76
- STD77
- MycobacteriaTuberculosis78
- AtypicalPneumonia78
- CMV79
- ViralMeningitis80
- RespiratoryViruses81
- HPV82
- MRSA82
4.2 Market Shares83
5. Market Trends 85
5.1 Problems withMolecularDiagnostics85
5.2 ExpectedGrowth per Segment86
6.3 OtherGrowth Areas90
5.4 Drivers forMolecularDiagnostics91
5.5 RestraintsforMolecularDiagnostics92
6. PoliticalInfluences93
6.1 Changesof ReimbursementPolicy93
6.2 Influenceof the EU IVD Act94 |
Related Report
|
View Cart
